# EDGAR Filing Document

**Accession Number:** 0001819790
**File Stem:** 0000000000-23-003218
**Filing Date:** 2023-3
**Character Count:** 9135
**Document Hash:** a5cbc2c3e3b6ce22d408161d4e25d1e5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-003218.hdr.sgml**: 20230516

**ACCESSION NUMBER**: 0000000000-23-003218

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230330

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tarsus Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001819790
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 814717861
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 15440 LAGUNA CANYON ROAD
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92618
- **BUSINESS PHONE:** (949) 409-9820

**MAIL ADDRESS:**
- **STREET 1:** 15440 LAGUNA CANYON ROAD
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92618
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001819790-23-000007

## Text-Extract

```

United States securities and exchange commission logo

                             March 30, 2023

       Leonard Greenstein
       Chief Financial Officer
       Tarsus Pharmaceuticals, Inc.
       15440 Laguna Canyon Road
       Suite 160
       Irvine, California 92618

                                                        Re: Tarsus
Pharmaceuticals, Inc.
                                                            Form 10-K for the
Fiscal Year Ended December 31, 2022
                                                            Filed March 17,
2023
                                                            File No. 001-39614

       Dear Leonard Greenstein:

              We have limited our review of your filing to the financial
statements and related
       disclosures and have the following comments. In some of our comments, we
may ask you to
       provide us with information so we may better understand your disclosure.

              Please respond to these comments within ten business days by
providing the requested
       information or advise us as soon as possible when you will respond. If
you do not believe our
       comments apply to your facts and circumstances, please tell us why in
your response.

                                                        After reviewing your
response to these comments, we may have additional comments.

       Form 10-K for the Fiscal Year Ended December 31, 2022

       Management's Discussion and Analysis of Financial Condition and Results
of Operations
       Components of our Results of Operations
       Research and Development Expenses, page 93

   1.                                                   Please provide more
disaggregated disclosures for your research and development
                                                        expenses by each
significant program. In this regard, we note that you disclosed at page
                                                        94 that you track your
external research and development expenses on a program-by-
                                                        program basis.
 Leonard Greenstein
FirstName  LastNameLeonard
Tarsus Pharmaceuticals, Inc. Greenstein
Comapany
March      NameTarsus Pharmaceuticals, Inc.
       30, 2023
March2 30, 2023 Page 2
Page
FirstName LastName
Financial Statements
Note 9. Out-License Agreement, page 126

2.       Please address the following comments with regard to your accounting
and disclosures for
         your Out-License of TP-03 Commercial Rights in Greater China with
LianBio
         Ophthalmology Limited.

                Describe all material terms of the agreement, including the
material rights and
              obligations of each party.
                Provide us an analysis of your revenue recognition under ASC
606, including your
              determination of the performance obligations, the transaction
price, the amount
              allocated to each performance obligation, and your revenue
recognition method (i.e.
              over time or point in time) for each performance obligation.
                Tell us who is responsible for the achievement of additional
TP-03 events discussed
              on page 22 which may result in additional consideration and
clarify that the
              additional consideration is not included in the transaction
price, if such is the case.
              Confirm that you have no further performance obligations
including any clinical
              work with respect to either TP-03 for the treatment of Demodex
blepharitis or MGD.
                Tell us if the license was determined to be distinct and your
basis for it.
                Clarify how you are accounting for the drug supply agreement
discussed on page 93
              and provide references within ASC 606 to support your accounting
treatment.
                Lastly, clarify what is included in the line item
"collaboration revenue" in your
              statement of operations.

         Please provide us your proposed future disclosures, as necessary.
       In closing, we remind you that the company and its management are
responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or
absence of action by the staff.

       You may contact Li Xiao at (202) 551-4391 or Mary Mast at (202) 551-3613
with any
questions.

                                                                Sincerely,

                                                                Division of
Corporation Finance
                                                                Office of Life
Sciences

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

CORPORATION FINANCE

# UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

March 30, 2023

Leonard Greenstein  
Chief Financial Officer  
Tarsus Pharmaceuticals, Inc.  
15440 Laguna Canyon Road  
Suite 160  
Irvine, California 92618

**Re: Tarsus Pharmaceuticals, Inc.  
Form 10-K for the Fiscal Year Ended December 31, 2022  
Filed March 17, 2023  
File No. 001-39614**

Dear Leonard Greenstein:

We have limited our review of your filing to the financial statements and related disclosures and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to these comments within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response.

After reviewing your response to these comments, we may have additional comments.

Form 10-K for the Fiscal Year Ended December 31, 2022

Management's Discussion and Analysis of Financial Condition and Results of Operations  
Components of our Results of Operations  
Research and Development Expenses, page 93

1. Please provide more disaggregated disclosures for your research and development expenses by each significant program. In this regard, we note that you disclosed at page 94 that you track your external research and development expenses on a program-by-program basis.

Leonard Greenstein
Tarsus Pharmaceuticals, Inc.
March 30, 2023
Page 2

# Financial Statements

# Note 9. Out-License Agreement, page 126

2. Please address the following comments with regard to your accounting and disclosures for your *Out-License of TP-03 Commercial Rights in Greater China* with LianBio Ophthalmology Limited.

- Describe all material terms of the agreement, including the material rights and obligations of each party.
- Provide us an analysis of your revenue recognition under ASC 606, including your determination of the performance obligations, the transaction price, the amount allocated to each performance obligation, and your revenue recognition method (i.e. over time or point in time) for each performance obligation.
- Tell us who is responsible for the achievement of additional TP-03 events discussed on page 22 which may result in additional consideration and clarify that the additional consideration is not included in the transaction price, if such is the case. Confirm that you have no further performance obligations including any clinical work with respect to either TP-03 for the treatment of Demodex blepharitis or MGD.
- Tell us if the license was determined to be distinct and your basis for it.
- Clarify how you are accounting for the drug supply agreement discussed on page 93 and provide references within ASC 606 to support your accounting treatment.
- Lastly, clarify what is included in the line item "*collaboration revenue*" in your statement of operations.

Please provide us your proposed future disclosures, as necessary.

In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

You may contact Li Xiao at (202) 551-4391 or Mary Mast at (202) 551-3613 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences